Manifaxine
Manifaxine is a dopamine and norepinephrine reuptake inhibitor that was under development for the treatment of depression and fatigue, but was discontinued. It was developed by GlaxoSmithKline.
Pharmacology[edit | edit source]
Manifaxine acts as a norepinephrine-dopamine reuptake inhibitor (NDRI). It inhibits the reuptake of dopamine and norepinephrine, thereby increasing their concentrations in the brain. This results in increased neurotransmission, which can help to alleviate symptoms of depression and fatigue.
Development and Discontinuation[edit | edit source]
Manifaxine was developed by GlaxoSmithKline for the treatment of depression and fatigue. However, the development of the drug was discontinued for unknown reasons. It is not currently available for medical use.
See Also[edit | edit source]
References[edit | edit source]
Manifaxine Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD